India
The patent office in India tofacitinib#india%20rejects%20patent%20on%20pfizer's%20arthritis%20drug">rejects Pfizer's petition for a patent on an arthritis drug, tofacitinib, re-affirming their rejection of the same drug in 2011. The drug is a chemical reformulation of the active compound in the medicine and thus the Indian Patent Office says that the company would have to establish that the compound for which it is seeking a patent is therapeutically more effective than the active compound.
Sources: Reuters